Literature DB >> 19799911

Nitric oxide inhibits endothelin-1-induced neonatal cardiomyocyte hypertrophy via a RhoA-ROCK-dependent pathway.

J Craig Hunter1, Asad Zeidan, Sabzali Javadov, Ana Kilić, Venkatesh Rajapurohitam, Morris Karmazyn.   

Abstract

Although nitric oxide (NO) has received extensive attention as an anti-hypertrophic agent the mechanisms underlying its regulation of endothelin-1 (ET-1) have not been fully elucidated. Since RhoA has been identified as an important mediator of cardiac hypertrophy and is inhibited by NO in vascular tissue, we sought to determine whether the anti-ET-1 effects of NO in cardiomyocytes were mediated via inhibition of the RhoA-ROCK cascade in the context of cardiac hypertrophy. Neonatal rat ventricular myocytes were cultured in the presence of ET-1 (10 nM) with or without pre-treatment with the NO donor S-nitroso-n-acetylpenicillamine (SNAP; 100 microM), 8-Br-cGMP (cGMP; 100 microM), the RhoA inhibitor C3 exoenzyme (C3; 30 ng/ml), or the ROCK inhibitor Y-27632 (10 microM). ET-1-induced cardiomyocyte hypertrophy was prevented by pre-treatment with SNAP, cGMP, C3, or Y-27632. The hypertrophic response to ET-1 was associated with significantly increased gene and protein expression of both NOS2 and NOS1 although NOS3 was unaffected. ET-1 treatment for 15 min increased membrane-bound RhoA 2.6-fold (p<0.05), which was prevented by both SNAP and cGMP (p<0.05). These effects were associated with a complete abrogation of ET-1-induced phosphorylation of the downstream target of RhoA, cofilin-2, that was mimicked by direct inhibition of RhoA and ROCK. In addition, confocal microscopy and Western blotting revealed that 24 h ET-1 treatment reduced the G- to F-actin ratio 67% (p<0.05) which was prevented by SNAP, cGMP, C3 and Y (p<0.05). Taken together, these results suggest that the anti-hypertrophic effects of NO are due, in part, to cGMP-dependent inhibition of the RhoA-ROCK-cofilin signalling pathway. These findings may be important in understanding the mechanisms of anti-ET-1 and anti-hypertrophic effects of NO as well as in the development of novel RhoA-targeted therapeutic interventions for treating cardiac hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19799911     DOI: 10.1016/j.yjmcc.2009.09.012

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  14 in total

Review 1.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

Review 2.  Rho kinase as a therapeutic target in cardiovascular disease.

Authors:  Michelle Surma; Lei Wei; Jianjian Shi
Journal:  Future Cardiol       Date:  2011-09

3.  Evodiamine Inhibits Angiotensin II-Induced Rat Cardiomyocyte Hypertrophy.

Authors:  Na He; Qi-Hai Gong; Feng Zhang; Jing-Yi Zhang; Shu-Xian Lin; Hua-Hua Hou; Qin Wu; An-Sheng Sun
Journal:  Chin J Integr Med       Date:  2017-09-05       Impact factor: 1.978

4.  Regulation on RhoA in vascular smooth muscle cells under inflammatory stimulation proposes a novel mechanism mediating the multiple-beneficial action of acetylsalicylic acid.

Authors:  Dong-Bo Li; Guo-Jie Yang; Hong-Wei Xu; Zhi-Xuan Fu; Shan-Wei Wang; Shen-Jiang Hu
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

5.  Prevention of RhoA activation and cofilin-mediated actin polymerization mediates the antihypertrophic effect of adenosine receptor agonists in angiotensin II- and endothelin-1-treated cardiomyocytes.

Authors:  Asad Zeidan; Xiaohong Tracey Gan; Ashley Thomas; Morris Karmazyn
Journal:  Mol Cell Biochem       Date:  2013-10-06       Impact factor: 3.396

6.  Modulatory Role of Nitric Oxide/cGMP System in Endothelin-1-Induced Signaling Responses in Vascular Smooth Muscle Cells.

Authors:  Georgia Kapakos; Ali Bouallegue; Grace Bou Daou; Ashok K Srivastava
Journal:  Curr Cardiol Rev       Date:  2010-11

7.  Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor.

Authors:  Eric E Essick; Flora Sam
Journal:  Int J Hypertens       Date:  2011-05-22       Impact factor: 2.420

8.  Elevated Levels of Asymmetric Dimethylarginine (ADMA) in the Pericardial Fluid of Cardiac Patients Correlate with Cardiac Hypertrophy.

Authors:  Zoltan Nemeth; Attila Cziraki; Sandor Szabados; Bernadett Biri; Sandor Keki; Akos Koller
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

Review 9.  The Function of Rho-Associated Kinases ROCK1 and ROCK2 in the Pathogenesis of Cardiovascular Disease.

Authors:  Svenja Hartmann; Anne J Ridley; Susanne Lutz
Journal:  Front Pharmacol       Date:  2015-11-20       Impact factor: 5.810

10.  Adiponectin Attenuates Angiotensin II-Induced Vascular Smooth Muscle Cell Remodeling through Nitric Oxide and the RhoA/ROCK Pathway.

Authors:  Wared Nour-Eldine; Crystal M Ghantous; Kazem Zibara; Leila Dib; Hawraa Issaa; Hana A Itani; Nabil El-Zein; Asad Zeidan
Journal:  Front Pharmacol       Date:  2016-04-07       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.